Search - tctmd.com

Displaying 121 - 128 of 128

Sort: Relevancy | Date

News Conference News ACC 2012

INFUSE-AMI: Bolus Abciximab Works, Thrombus Aspiration Doesn’t for Large STEMI

Jason Kahn

March 25, 2012

News Conference News ACC 2012

EXOME: New Genetic Sequencing Zeroes in on Clopidogrel Response Variants

March 25, 2012

Presentation ACC 2012

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

Presenter: Myeong-Ki Hong

March 25, 2012

News Conference News ACC 2012

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Jason Kahn

March 24, 2012

Presentation ACC 2012

RESET Study: Pharmacodynamic Effects of Switching Therapy in PCI Patients with High on Treatment Platelet Reactivity and Genotype Variation: High Clopidogrel Dose versus Prasugrel

Presenter: Gennaro Sardella

March 24, 2012

News Conference News ACC 2012

Prasugrel Effective in Stable Patients With Poor Response to Clopidogrel

Jason Kahn

March 24, 2012

Presentation ACC 2012

First Pharmacogenomic Analysis Using Whole Exome Sequencing to Identify Novel Genetic Determinants of Clopidogrel

Presenter: Matthew Price

March 24, 2012

Presentation ACC 2012

Adjunctive Cilostazol Versus Double Dose Clopidogrel After PCI with Drug Eluting Stent: The HOST-ASSURE Randomized Trial

Presenter: Hyo-Soo Kim

March 24, 2012

Advertisement

INFUSE-AMI: Bolus Abciximab Works, Thrombus Aspiration Doesn’t for Large STEMI

EXOME: New Genetic Sequencing Zeroes in on Clopidogrel Response Variants

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

RESET Study: Pharmacodynamic Effects of Switching Therapy in PCI Patients with High on Treatment Platelet Reactivity and Genotype Variation: High Clopidogrel Dose versus Prasugrel

Prasugrel Effective in Stable Patients With Poor Response to Clopidogrel

First Pharmacogenomic Analysis Using Whole Exome Sequencing to Identify Novel Genetic Determinants of Clopidogrel

Adjunctive Cilostazol Versus Double Dose Clopidogrel After PCI with Drug Eluting Stent: The HOST-ASSURE Randomized Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content